Bond Screener
Regeneron
LEI 549300RCBFWIRX3HYQ56
Organization name
Regeneron Pharmaceuticals Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
Public debt
2,000 mln USD
New to Cbonds? · Take a 90-second tour of the platform.
Discover what you can do with Cbonds
Everything you need for fixed income research and monitoring.
- 00:23 Coverage
- 00:40 Bond screener
- 00:54 Parameters
- 01:10 Watchlist, Mobile app
- 01:15 Excel Add-in
Trading Schedule Issuer map
Quotes
/
/
/
pcs.
pcs.
pcs.
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Quotes provided by information providers are indicative in nature
Profile
|
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.
|
General information
-
Organization nameRegeneron Pharmaceuticals Inc
-
Organization statusOperating organization
-
Address777 Old Saw Mill River Road, Tarrytown, USA, 10591
-
Site
News
-
Regeneron Pharmaceuticals (NASDAQ: REGN) Faces Investor Lawsuit Following Clinical Trial Setback14/08/2026
-
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Maintains Strong Position in Biotech Sector09/03/2026
-
Regeneron Pharmaceuticals: A Strong Contender in the Biotech Industry06/03/2026
-
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Quarterly Earnings Preview29/01/2026
-
Regeneron: Q4 2025 Ipr&d Charge, Regulation Fd Disclosure, Financial Statements And Exhibits12/01/2026
IFRS/US GAAP reports
| 2026 | |
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |
Show more
Hide
Authorization required
You need to request access
Stocks
General information
-
Organization nameRegeneron Pharmaceuticals Inc
-
Organization statusOperating organization
-
Address777 Old Saw Mill River Road, Tarrytown, USA, 10591
-
Site
Codes
-
LEI549300RCBFWIRX3HYQ56
-
SIC2834 PHARMACEUTICAL PREPARATIONS
-
NACE*** ***
-
NAICS*** ***
-
CIK0000872589
-
EIN13-3444607
